识别针对胰岛素受体异型A的向抑制的反感性寡核酸
Christopher A Galifi1, Ryan J Dikdan2, Divyangi Kantak1
1Department of Pharmacology, Physiology, & Neuroscience, Center for Cell Signaling and Cancer Institute of New Jersey, Rutgers Biomedical and Health Sciences, Newark, NJ, United States.
Frontiers in oncology
|April 30, 2025
概括
研究人员开发了一种反感性寡核酸 (ASO),可以选择性地向与癌症相关的胰岛素受体异型A (IR-A). 这种新型的ASO有效地减少了各种癌细胞中的IR-A表达,提供了潜在的治疗应用.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 药物发现 药物发现
背景情况:
- 胰岛素受体 (IR) 有两种异型:IR-A和IR-B.
- IR-A与侵袭性癌症有关,但由于与IR-B的同质性,选择性向具有挑战性.
- IR-B主要参与代谢信号传递.
研究的目的:
- 开发和评估一种反感性寡核酸 (ASO) 用于选择性向IR-A异型.
- 评估ASO在降低癌症细胞系中IR-AmRNA和蛋白质水平方面的有效性.
- 研究ASO作为研究工具和治疗剂的潜力.
主要方法:
- 产生针对IR-A特定拼接接口的反意义寡核酸 (ASO).
- ASO转化为MDA-MB-231 (乳腺),22Rv1 (前列腺) 和HS822.T (尤文肉瘤) 癌细胞系.
- 在ASO治疗后评估IR-A和IR-BmRNA和蛋白质水平,包括评估体操分娩.
主要成果:
- 一种ASO变异表明IR-AmRNA的选择性减少,对IR-B的影响最小.
- 在MDA-MB-231细胞中实现了有效的IR-A淘汰,并维持了一周.
- ASO在Hs822.T和22Rv1细胞系中显示出有效性,包括通过体操分娩.
结论:
- 一个针对IR-A的ASO已经成功开发出来,它提供了选择性的淘汰,对IR-B的目标外影响最小.
- 这种针对IR-A的ASO是研究癌症中的IR-A功能的一个有价值的研究工具.
- 开发的ASO具有潜在的治疗价值,可以抑制癌细胞中的瘤性IR-A活性.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.0K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.0K
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Insulin: Biosynthesis, Chemistry, and Preparation
303
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
303
Oral Hypoglycemic Agents: Biguanides and Glitazones
133
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
133


